and Kyowa Kirin’s anti-CCR4 antibody Poteligeo (mogamulizumab) – the last drug to be approved by the FDA for CTCL in 2018 – have been shown to drive the disease into remission. A phase 3 ...

Pembrolizumab demonstrated clinical activity in patients with mycosis fungoides (MF) and Sézary syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma (CTCL), with nearly half of ...

Shanghai Pharmaceuticals Holding Co. Ltd. has identified C-C chemokine receptor type 4 (CCR4) antagonists reported to be useful for the treatment of asthma, allergic rhinitis, atopic dermatitis, ...

This rapid response is a distinct advantage of HyBryte™ therapy, with many other therapies used in CTCL taking up to six to 12 months to generate a clinically meaningful treatment response.

This rapid response is a distinct advantage of HyBryteTM therapy, with many other therapies used in CTCL taking up to six to 12 months to generate a clinically meaningful treatment response.